New pill shows promise against tough cancers in early trial

NCT ID NCT05873686

Recruiting now Disease control Sponsor: Nuvectis Pharma, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study tests a new oral drug called NXP900 in people with advanced solid tumors (like lung, kidney, or mesothelioma) that have not responded to standard treatments. The trial has two parts: first, finding the right dose, and then seeing if the drug shrinks tumors. It is a first-in-human study, so safety and effectiveness are still unknown.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NXP900 (an oral drug that blocks certain cancer-driving proteins)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 140 participants, so the drug may not prove effective or safe in larger studies. Side effects are unknown at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma carcinoma kidney cancer lung adenocarcinoma mesothelioma neoplasm non-small cell lung carcinoma non-small cell squamous lung carcinoma renal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR MESOTHELIOMA NON-SMALL CELL LUNG ADENOCARCINOMA NON-SMALL CELL SQUAMOUS LUNG CANCER NSCLC (NON-SMALL CELL LUNG CANCER) RENAL CANCER

Contacts and locations

Locations

Cleveland Clinic
RECRUITING

Cleveland, Ohio, 44195, United States
Mayo Clinic
RECRUITING

Phoenix, Arizona, 85054, United States
Mayo Clinic
RECRUITING

Jacksonville, Florida, 32224, United States
Mayo Clinic Rochester
RECRUITING

Rochester, Minnesota, 55905, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10021, United States
NEXT Oncology Dallas
RECRUITING

Irving, Texas, 75039, United States
NEXT Oncology Houston
RECRUITING

Houston, Texas, 77054, United States
NEXT Oncology Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
Oregon Health and Science University
RECRUITING

Portland, Oregon, 97239, United States
Sarah Cannon Research Institute at HealthONE
RECRUITING

Denver, Colorado, 80218, United States
The Royal Marsden NHS Foundation and Trust
COMPLETED

London, SW3 6JJ, United Kingdom
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
UC San Diego Moores Cancer Center
RECRUITING

La Jolla, California, 92093, United States
University of Chicago
RECRUITING

Chicago, Illinois, 60637, United States
Western General Hospital - NHS Lothian
COMPLETED

Edinburgh, EH4 2XU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.